These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28406576)

  • 1. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
    Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
    Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
    Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
    Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
    Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond].
    Narita K
    Yakugaku Zasshi; 2022; 142(9):917-926. PubMed ID: 36047217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS; Wilson AJ; Parl AK; Khabele D
    Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
    Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA
    Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
    Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
    Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
    Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
    Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
    Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
    Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity.
    Fukui Y; Narita K; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
    Eur J Med Chem; 2014 Apr; 76():301-13. PubMed ID: 24589486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.